Denali Therapeutics Inc. – NASDAQ:DNLI

Add to watchlist

$14.8

-5.80

-28.19%

Market closed

Open in about 2 hours

-9.84%

month

-9.84%

quarter

-7.20%

year

Market Cap	3.02B
Enterprise value	3.01B

P/E	-8.61
EV/Sales	27.75
EV/EBITDA	-10.00
Price/Sales	29.20
Price/Book	3.03
PEG ratio	0.97
EPS	-0.91

Revenue	N/A
EBITDA	-201.58M
Income	-137.24M
Revenue Q/Q	-100%
Revenue Y/Y	-109.51%

Profit margin	-300.55%
Oper. margin	-314.16%
Gross margin	0%
EBIT margin	-314.16%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Denali Therapeutics Stock Forecast

M Q Y

Last Year

$35

Potential upside: 136.48%

Analysts Price target
Financials & Ratios estimates

Denali Therapeutics Inc. (NASDAQ:DNLI): Profit margin
Jun 2023	294.12M	183.38M	62.35%
Sep 2023	1.26M	-99.35M	-7841.59%
Dec 2023	-305.04M	-119.47M	39.17%
Mar 2024	0	-101.80M

Denali Therapeutics Inc. (NASDAQ:DNLI): Debt to assets
Jun 2023	1305734000	118.90M	9.11%
Sep 2023	1236777000	118.44M	9.58%
Dec 2023	1153917000	122.96M	10.66%
Mar 2024	1581091000	125.61M	7.94%

Denali Therapeutics Inc. (NASDAQ:DNLI): Cash Flow
Jun 2023	-113.16M	168.06M	9.01M
Sep 2023	-87.36M	100.90M	2.49M
Dec 2023	-98.65M	73.04M	4.70M
Mar 2024	-113.62M	-453.18M	500.27M

Denali Therapeutics alternative data

Denali Therapeutics Inc. (NASDAQ:DNLI): Employee count
Aug 2023	430
Sep 2023	438
Oct 2023	438
Nov 2023	438
Dec 2023	447
Jan 2024	447
Feb 2024	447
Mar 2024	445
Apr 2024	445
May 2024	445
Jun 2024	375
Jul 2024	375

Denali Therapeutics
Hedge Funds Holdings Q1 2023

45.15% -40.49%

of DNLI is owned by hedge funds

117 -76

hedge funds hold DNLI stock

56.67M -49.05M

shares is hold by hedge funds

DNLI hedge funds holdings changes

Denali Therapeutics
Insider Trading

Denali Therapeutics Inc. (NASDAQ:DNLI): Insider trades (number of shares)
Period	Buy	Sel
Dec 2023	0	1666
Jan 2024	0	54787
Feb 2024	0	41038
Mar 2024	0	1666
Apr 2024	0	94166
May 2024	0	1674
Jun 2024	0	2146
Jul 2024	0	33080
Aug 2024	0	39407
Sep 2024	0	34100
Oct 2024	0	40000
Nov 2024	0	79099

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	25 Nov 2024	HO CAROLE officer: Chief Me..	Common Stock	17,845	$0.68	$12,135
Option	25 Nov 2024	HO CAROLE officer: Chief Me..	Stock Option (right to buy)	17,845	$0.68	$12,135
Option	22 Nov 2024	SCHUTH ALEXANDER O. officer: COFO and..	Common Stock	20,516	$0.68	$13,951
Option	22 Nov 2024	SCHUTH ALEXANDER O. officer: COFO and..	Stock Option (right to buy)	20,516	$0.68	$13,951
Option	11 Nov 2024	SCHENKEIN DAVID P director director	Common Stock	47,165	$18	$848,970
Sale	11 Nov 2024	SCHENKEIN DAVID P director director	Common Stock	27,129	$32.09	$870,570
Sale	11 Nov 2024	SCHENKEIN DAVID P director director	Common Stock	32,312	$32.87	$1,062,095
Option	11 Nov 2024	SCHENKEIN DAVID P director director	Stock Option (right to buy)	47,165	$18	$848,970
Option	7 Nov 2024	SCHUTH ALEXANDER O. officer: COFO and..	Common Stock	15,558	$5.28	$82,146
Sale	7 Nov 2024	SCHUTH ALEXANDER O. officer: COFO and..	Common Stock	12,333	$29.68	$366,043

DNLI insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application MODIFIED RELEASE FORMULATION OF A PYRIMIDINYLAMINO-PYRAZOLE COMPOUND, AND METHODS OF TREATMENT Filling date: 29 May 2020 Issue date: 11 Aug 2022	29 May 2020	11 Aug 2022
Application	Application PROGRANULIN VARIANTS Filling date: 18 Mar 2022 Issue date: 14 Jul 2022	18 Mar 2022	14 Jul 2022
Application	Application COMPOUNDS, COMPOSITIONS, AND METHODS Filling date: 10 Apr 2020 Issue date: 14 Jul 2022	10 Apr 2020	14 Jul 2022
Application	Application PROGRANULIN VARIANTS Filling date: 17 Mar 2022 Issue date: 7 Jul 2022	17 Mar 2022	7 Jul 2022
Grant	Grant Utility: Anti-Tau antibodies and methods of use thereof Filling date: 16 Aug 2019 Issue date: 28 Jun 2022	16 Aug 2019	28 Jun 2022
Application	Application FORMULATIONS OF PROTEIN MOLECULES COMPRISING IDURONATE 2-SULFATASE Filling date: 3 Apr 2020 Issue date: 16 Jun 2022	3 Apr 2020	16 Jun 2022
Application	Application ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF Filling date: 17 Sep 2021 Issue date: 9 Jun 2022	17 Sep 2021	9 Jun 2022
Application	Application COMPOUNDS, COMPOSITIONS AND METHODS Filling date: 12 Feb 2020 Issue date: 9 Jun 2022	12 Feb 2020	9 Jun 2022
Application	Application COMPOUNDS, COMPOSITIONS AND METHODS Filling date: 1 Feb 2022 Issue date: 19 May 2022	1 Feb 2022	19 May 2022
Application	Application COMPOUNDS, COMPOSITIONS, AND METHODS Filling date: 13 Aug 2021 Issue date: 5 May 2022	13 Aug 2021	5 May 2022

Denali Therapeutics
Executives

Insider	Age	Compensation
Dr. Ryan J. Watts Ph.D. (1976) Co-Founder, Pres, Chief Executive Officer & Director	49	$1,250,000
Mr. Steve Edward Krognes (1968) Chief Financial Officer & Treasurer	57	$882,960
Dr. Carole Ho (1973) Chief Medical Officer & Head of Devel.	52	$835,080
Dr. Alexander O. Schuth M.D. (1973) Co-Founder, Chief Operating Officer & Sec.	52	$820,320
Dr. Marc Tessier-Lavigne Ph.D. (1960) Co-Founder, Chairman of Scientific Advisory Board & Independent Director	65	$59,500

Denali Therapeutics
Latest News

Monday, 9 December 2024
06:49	Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report?	zacks.com
Friday, 6 December 2024
10:50	Denali Starts Dosing in Phase II Parkinson's Disease Study	zacks.com
Saturday, 16 November 2024
08:56	Denali Has A Neurodegenerative Edge Despite Market Skepticism	seekingalpha.com
Friday, 8 November 2024
11:10	Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging	zacks.com
Wednesday, 6 November 2024
16:01	Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights	globenewswire.com
Tuesday, 29 October 2024
11:06	Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release	zacks.com
Monday, 16 September 2024
12:26	Strength Seen in Denali Therapeutics (DNLI): Can Its 10.1% Jump Turn into More Strength?	zacks.com
Wednesday, 4 September 2024
12:41	Denali Plans to File for Accelerated Approval of Hunter Syndrome Drug	zacks.com
Tuesday, 3 September 2024
08:00	Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)	globenewswire.com
Monday, 19 August 2024
22:55	Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology	seekingalpha.com
Wednesday, 14 August 2024
14:00	Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration	globenewswire.com
Tuesday, 6 August 2024
10:55	Wall Street Analysts Believe Denali Therapeutics (DNLI) Could Rally 79.62%: Here's is How to Trade	zacks.com
Thursday, 1 August 2024
06:45	Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights	globenewswire.com
Tuesday, 23 July 2024
07:16	Denali Therapeutics (DNLI) Stock Jumps 9.7%: Will It Continue to Soar?	zacks.com
Monday, 8 July 2024
19:09	3 Longevity Stocks to Buy for Anti-Aging Breakthroughs	investorplace.com
Friday, 28 June 2024
09:40	Denali (DNLI) Outperforms Industry in 3 Months: Here's Why	zacks.com
Monday, 24 June 2024
10:10	Denali Therapeutics (DNLI) Moves 5.8% Higher: Will This Strength Last?	zacks.com
Thursday, 6 June 2024
12:36	Why Is Denali Therapeutics (DNLI) Up 15.6% Since Last Earnings Report?	zacks.com
Tuesday, 4 June 2024
14:21	Denali's (DNLI) Candidate Selected for FDA's START Pilot Program	zacks.com
Monday, 3 June 2024
08:00	Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies	globenewswire.com
Monday, 13 May 2024
12:30	Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data	Seeking Alpha
Wednesday, 8 May 2024
09:21	Denali (DNLI) Q1 Earnings Miss, Pipeline Progress in Focus	Zacks Investment Research
Tuesday, 9 April 2024
09:51	Why Denali Therapeutics (DNLI) Stock Might be a Great Pick	Zacks Investment Research
Thursday, 14 March 2024
16:30	To the Moon and Beyond: 7 Stocks With Cosmic Potential	InvestorPlace
Wednesday, 6 March 2024
22:05	Denali: Leveraging Transport Vehicle Technology For Neurological Gains	Seeking Alpha
08:51	Top 3 Wall Street stock picks for March	Finbold
Wednesday, 28 February 2024
09:11	Denali's (DNLI) Q4 Earnings Miss, Pipeline in Focus, Stock Up	Zacks Investment Research
Thursday, 8 February 2024
09:10	3 Biotech Stocks to Buy for the Next Bull Run: February 2024	InvestorPlace
Friday, 26 January 2024
11:01	Denali's (DNLI) Pipeline Progresses Despite Stiff Competition	Zacks Investment Research
Tuesday, 2 January 2024
13:57	3 Biotech Stocks at the Forefront of the Quest for Eternal Youth	InvestorPlace

Ideas & Opinions

Seeking Alpha 30 Jan 2025

Voyager: Crossing The Blood-Brain Barrier, Competitors, And Investment Relevance
Seeking Alpha 10 Jan 2025

NervGen In Spotlight As It Approaches Clinical Proof Of Concept Readout For Spinal Cord Regeneration
Seeking Alpha 9 Jan 2025

Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains
Seeking Alpha 29 May 2024

Gain Therapeutics: Phase 1 Readout Awaits For Parkinson's Drug With Great Potential
Seeking Alpha 13 May 2024

Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data
Seeking Alpha 29 Nov 2023

Biogen: LAQEMBI's $10 Billion Potential
Seeking Alpha 26 Oct 2023

Capitalizing On Inflammation's Role In Neurological Disease Part 2: INmune Bio
Seeking Alpha 2 Oct 2023

Denali's New Summit: Changing Hunter Syndrome Landscape
Seeking Alpha 14 Aug 2023

Capitalizing On Inflammation's Role In Neurological Disease Part 1: Coya Therapeutics
Seeking Alpha 23 Jul 2023

MPS II And Beyond: Implications Of Denali's Promising Pipeline

Frequently Asked Questions (FAQ)

What's the price of Denali Therapeutics stock today?

One share of Denali Therapeutics stock can currently be purchased for approximately $14.8.
When is Denali Therapeutics's next earnings date?

Unfortunately, Denali Therapeutics's (DNLI) next earnings date is currently unknown.
Does Denali Therapeutics pay dividends?

No, Denali Therapeutics does not pay dividends.
How much money does Denali Therapeutics make?

Denali Therapeutics has a market capitalization of 3.02B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 204.74% to 330.53M US dollars.
What is Denali Therapeutics's stock symbol?

Denali Therapeutics Inc. is traded on the NASDAQ under the ticker symbol "DNLI".
What is Denali Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Denali Therapeutics?

Shares of Denali Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Denali Therapeutics's key executives?
Denali Therapeutics's management team includes the following people:
- Dr. Ryan J. Watts Ph.D. Co-Founder, Pres, Chief Executive Officer & Director(age: 49, pay: $1,250,000)
- Mr. Steve Edward Krognes Chief Financial Officer & Treasurer(age: 57, pay: $882,960)
- Dr. Carole Ho Chief Medical Officer & Head of Devel.(age: 52, pay: $835,080)
- Dr. Alexander O. Schuth M.D. Co-Founder, Chief Operating Officer & Sec.(age: 52, pay: $820,320)
- Dr. Marc Tessier-Lavigne Ph.D. Co-Founder, Chairman of Scientific Advisory Board & Independent Director(age: 65, pay: $59,500)
Is Denali Therapeutics founder-led company?

Yes, Denali Therapeutics is a company led by its founders Dr. Ryan J. Watts Ph.D., Dr. Alexander O. Schuth M.D. and Dr. Marc Tessier-Lavigne Ph.D..
How many employees does Denali Therapeutics have?

As Jul 2024, Denali Therapeutics employs 375 workers, which is 16% less then previous quarter.
When Denali Therapeutics went public?

Denali Therapeutics Inc. is publicly traded company for more then 7 years since IPO on 8 Dec 2017.
What is Denali Therapeutics's official website?

The official website for Denali Therapeutics is denalitherapeutics.com.
Where are Denali Therapeutics's headquarters?

Denali Therapeutics is headquartered at 161 Oyster Point Boulevard, South San Francisco, CA.
How can i contact Denali Therapeutics?

Denali Therapeutics's mailing address is 161 Oyster Point Boulevard, South San Francisco, CA and company can be reached via phone at +65 08668548.
What is Denali Therapeutics stock forecast & price target?

Based on 6 Wall Street analysts` predicted price targets for Denali Therapeutics in the last 12 months, the avarage price target is $35. The average price target represents a 136.48% change from the last price of $14.8.

Denali Therapeutics Inc.

denalitherapeutics.com

Exchange:

NASDAQ

Full time employees:

390

Industry:

Biotechnology

Sector:

Healthcare

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

+65 08668548

161 Oyster Point Boulevard
South San Francisco, CA 94080

CIK: 0001714899
ISIN: US24823R1059
CUSIP: 24823R105